Physician
Nashville Pain & Wellness Center PLLC
Nashville Pain & Wellness Center PLLC was paid $1.46M by Medicaid between Jan 2018 and Dec 2024, across 54 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 49% of everything it billed.
33Billing provider infoNASHVILLE PAIN & WELLNESS CENTER PLLC
DICKSON, TN 37055
DICKSON, TN 37055
33aNPI1982949814assigned 12/04/2012
33bProvider typeAnesthesiology Physician
28Total paid$1.46M
24GClaims111,357
24DCodes billed54
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Anesthesiology Physician providers in Tennessee
Rank by total paid#7 of 64
Median peer was paid$14K
This provider vs. median101×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 17,645 | $289K | |
| 2019 | 23,046 | $279K | |
| 2020 | 21,359 | $280K | |
| 2021 | 22,915 | $285K | |
| 2022 | 12,732 | $165K | |
| 2023 | 7,681 | $83K | |
| 2024incomplete | 5,979 | $76K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 49% | 57,120 | 46,570 | $715K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 21% | 16,007 | 12,932 | $302K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 11% | 8,018 | 7,571 | $155K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 2.6% | 1,472 | 802 | $38K |
| 64483 | 2.5% | 544 | 424 | $37K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.4% | 2,866 | 2,761 | $35K |
| 80305 | 2.1% | 11,435 | 9,781 | $31K | |
| 62369 | <1% | 740 | 592 | $13K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 852 | 664 | $12K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 216 | 187 | $12K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | <1% | 368 | 312 | $11K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,081 | 938 | $11K |
42 more codes
| 27096 | <1% | 137 | $9K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 125 | $8K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 378 | $8K |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 3,052 | $6K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 505 | $6K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 183 | $6K |
| 76942 | <1% | 402 | $5K | |
| 99152 | <1% | 513 | $5K | |
| 99177 | <1% | 821 | $4K | |
| L0637 | Lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panels, posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panels, produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | <1% | 17 | $4K |
| 62370 | <1% | 189 | $4K | |
| 92552 | <1% | 197 | $3K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 94 | $3K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 25 | $2K |
| 64493 | <1% | 90 | $2K | |
| 99383 | <1% | 22 | $2K | |
| 90686 | <1% | 381 | $1K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 492 | $885.27 |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 91 | $877.72 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 58 | $839.14 |
| 87428 | <1% | 14 | $826.67 | |
| 96127 | <1% | 216 | $820.33 | |
| 64494 | <1% | 88 | $759.11 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 60 | $712.86 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 58 | $394.20 |
| 96160 | <1% | 170 | $359.95 | |
| 90461 | <1% | 175 | $258.84 | |
| 90670 | <1% | 50 | $258.51 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 694 | $141.02 |
| 95991 | <1% | 13 | $128.37 | |
| 90698 | <1% | 19 | $123.66 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 12 | $107.67 |
| 90680 | <1% | 17 | $105.31 | |
| 99442 | <1% | 16 | $104.83 | |
| 20611 | <1% | 16 | $93.60 | |
| 96161 | <1% | 31 | $91.19 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 715 | $33.30 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 226 | $33.10 |
| 64495 | <1% | 14 | $8.00 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 56 | $4.28 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 62 | $0.24 |
| 3008F | 0% | 144 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialYELAMELI, MADHU (MEDICAL DIRECTOR)